Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2684034 | 1.00 | GABRA5 (0.74) | GABRA5LMNAPTGS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL2685727 | 0.86 | GABRA5 (1.00) | GABRA5LMNAPTGS2RAB9AMAPT | |
| SCHEMBL2685719 | 0.86 | GABRA5 (1.00) | GABRA5LMNAPTGS2RAB9AMAPT | |
| SCHEMBL2685723 | 0.84 | GABRA5 (0.73) | GABRA5LMNAPTGS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4402982 | 0.80 | GABRA5 (1.00) | GABRA5GABRG2GABRB3KCNH2PPARA | |
| SCHEMBL2685279 | 0.78 | GABRA5 (0.77) | GABRA5SMN1; SMN2ALDH1A1NPSR1KDM4E | |
| SCHEMBL2685284 | 0.78 | GABRA5 (0.77) | GABRA5SMN1; SMN2ALDH1A1NPSR1KDM4E | |
| SCHEMBL2685481 | 0.71 | PTGS2 (0.49) | GABRA5LMNAPTGS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL13754468 | 0.70 | PTGS2 (0.55) | GABRA5LMNAPTGS2CA1CA2 | |
| SCHEMBL9730326 | 0.67 | HMGCR (0.51) | GABRA5PTGS2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638035-B1 | Triazole derivatives as ligands for Gaba receptors | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | claimed |
| US-8697696-B2 | Triazole compounds II | ROCHE PALO ALTO LLC (US) | 2014-04-15 | — | — | US | claimed |
| EP-2638035-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | claimed |
| CN-103189370-A | Triazole derivatives as ligands for GABA receptors | HOFFMANN LA ROCHE | 2013-07-03 | — | — | CN | claimed |
| WO-2012062623-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | claimed |
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | claimed |
| EP-2638035-B1 | Triazole derivatives as ligands for Gaba receptors | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-8697696-B2 | Triazole compounds II | ROCHE PALO ALTO LLC (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2638035-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| CN-103189370-A | Triazole derivatives as ligands for GABA receptors | HOFFMANN LA ROCHE | 2013-07-03 | — | — | CN | disclosed |
| WO-2012062623-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | GABRA5, GABRA1, GABRA3 | GABRA5 1/4885LMNA 4532/4885PTGS2 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.